SCHEMBL6985255

SCHEMBL6985255

CC(C)(C)[C@H](NS(=O)(=O)c1ccc2ccccc2c1)C(=O)N[C@H](CO)Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 1/20 0.49
CYP3A4 P08684 1/20 0.48
MAPK1 P28482 1/20 0.48
F2 P00734 6/20 0.47
NPY5R Q15761 1/20 0.45
SLC1A3 P43003 1/20 0.44
SLC1A2 P43004 1/20 0.44
SLC1A1 P43005 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MAPT P10636 1/20 0.43
POLB P06746 1/20 0.43
LARS1 Q9P2J5 1/20 0.42
PLAT P00750 1/20 0.41
CYP19A1 P11511 1/20 0.40
PIN1 Q13526 1/20 0.40
ADAMTS4 O75173 1/20 0.40
MMP13 P45452 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3906292 0.85 ADAM17 (0.48) ADAM17F2NPY5RSLC1A3SLC1A2
SCHEMBL1770561 0.79 ADAM17 (0.60) ADAM17CYP3A4F2SLC1A3SLC1A2
SCHEMBL1770556 0.79 ADAM17 (0.60) ADAM17CYP3A4F2SLC1A3SLC1A2
SCHEMBL6979815 0.79 SLC1A3 (0.60) ADAM17CYP3A4F2SLC1A3SLC1A2
SCHEMBL3914487 0.76 CAPN1 (0.62) ADAM17F2SLC1A3SLC1A2SLC1A1
SCHEMBL6951280 0.76 F2 (0.54) F2NPY5RSLC1A3SLC1A2SLC1A1
SCHEMBL7786990 0.74 BCL2 (0.51) F2POLBPIN1
SCHEMBL7789327 0.74 ALDH1A1 (0.57) MAPK1F2ALDH1A1PIN1
SCHEMBL7789330 0.74 ALDH1A1 (0.57) MAPK1F2ALDH1A1PIN1
SCHEMBL7786988 0.74 BCL2 (0.51) F2POLBPIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0927716-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-05-07 EP disclosed
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed